TY - JOUR
T1 - Ultra-Low Temperature Cryoablation for Atrial Fibrillation
T2 - Primary Outcomes for Efficacy and Safety: The Cryocure-2 Study
AU - de Potter, Tom
AU - Klaver, Martijn
AU - Babkin, Alex
AU - Iliodromitis, Konstantinos
AU - Hocini, Meleze
AU - Cox, Jim
AU - Boersma, Lucas
N1 - Funding Information: All study-related costs were funded by Adagio Medical. Dr De Potter has received consulting fees from and owns equity options in Adagio Medical. Dr Babkin has served as a consultant and is a former employee of Adagio Medical. Dr Cox is co-founder and Director of Adagio Medical. Dr Boersma has received consulting fees from Adagio Medical. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: © 2022 The Authors
PY - 2022/8/1
Y1 - 2022/8/1
N2 - Ultra-low temperature cryoablation (ULTC) is a novel ablation modality aiming to combine the effectiveness of surgical lesion delivery with percutaneous safety to improve outcomes in catheter ablations of atrial fibrillation, particularly in persistent AF (PsAF). In the Cryocure-2 study (NCT02839304) 78 patients (56.4% PsAF) received ULTC pulmonary vein isolation plus posterior wall ablation, and linear left and right atrial lesions as needed. The safety and acute success of ULTC appear consistent with current catheter ablation techniques and, together with Kaplan-Meier 85.9% 1-year freedom from AF observed in Cryocure-2 PsAF patients, warrant further evaluation in larger clinical trials, which are currently ongoing.
AB - Ultra-low temperature cryoablation (ULTC) is a novel ablation modality aiming to combine the effectiveness of surgical lesion delivery with percutaneous safety to improve outcomes in catheter ablations of atrial fibrillation, particularly in persistent AF (PsAF). In the Cryocure-2 study (NCT02839304) 78 patients (56.4% PsAF) received ULTC pulmonary vein isolation plus posterior wall ablation, and linear left and right atrial lesions as needed. The safety and acute success of ULTC appear consistent with current catheter ablation techniques and, together with Kaplan-Meier 85.9% 1-year freedom from AF observed in Cryocure-2 PsAF patients, warrant further evaluation in larger clinical trials, which are currently ongoing.
KW - atrial fibrillation ablation
KW - ultra-low temperature
UR - http://www.scopus.com/inward/record.url?scp=85135953103&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.jacep.2022.05.017
DO - https://doi.org/10.1016/j.jacep.2022.05.017
M3 - Review article
C2 - 35907755
SN - 2405-500X
VL - 8
SP - 1034
EP - 1039
JO - JACC: Clinical Electrophysiology
JF - JACC: Clinical Electrophysiology
IS - 8
ER -